FOXO4-DRI
D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction, used in cellular-senescence research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-FOXO4-2 · ≥99% (see COA) · Lyophilised powder
Note: Confirm identity (FOXO4-DRI) and sequence with the supplier.
FOXO4-DRI overview
FOXO4-DRI is a D-amino-acid, retro-inverso peptide based on a FOXO4 sequence. The supplier lists it as 'FOXO4'; confirm it is FOXO4-DRI. It is supplied as a lyophilised solid for in-vitro research.
FOXO4-DRI research background
Evidence status: Findings summarised here come from published cell-culture and animal research only; no controlled human studies were identified. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- FOXO4-DRI is a D-retro-inverso peptide designed by Baar, de Keizer and colleagues (2017) to disrupt the interaction between FOXO4 and p53 in senescent cells [1].
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
Research areas & model types
| Research area | Model type | Summary |
|---|---|---|
| Chemotoxicity and ageing models | Mouse (fast-ageing XpdTTD/TTD and naturally aged) | [1] |
| Senescent Leydig cells | In vitro; aged mice | [2] |
| Pulmonary fibrosis | Mouse (bleomycin); in vitro fibroblasts | [3] |
| Expanded chondrocytes | In vitro (human cells) | Senescent cells were reduced, but chondrogenic potential was not enhanced [4]. |
| Keloid fibroblasts | In vitro | [5] |
Human clinical research status
- No human trials were identified. It is not an approved medicine.
Safety observations reported in studies
- The original study described conditions under which the peptide was tolerated in mice [1]. No human safety data exist.
Known limitations
- The evidence is preclinical only.
- Identity must be confirmed (the supplier listing reads 'FOXO4').
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- Researchers have proposed that selectively eliminating senescent cells ('senolysis') via FOXO4–p53 disruption could restore tissue homeostasis [1].
Open scientific questions
- How selective is it across senescent cell types?
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Baar MP, Brandt RMC, Putavet DA et al.. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017. PubMed 28340339 · doi:10.1016/j.cell.2017.02.031
- Zhang C, Xie Y, Chen H et al.. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020. PubMed 31959736 · doi:10.18632/aging.102682
- Han X, Yuan T, Zhang J et al.. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med. 2022. PubMed 35510614 · doi:10.1111/jcmm.17333
- Huang Y, He Y, Makarcyzk MJ et al.. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021. PubMed 33996787 · doi:10.3389/fbioe.2021.677576
- Kong YX, Li ZS, Liu YB et al.. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025. PubMed 39994346 · doi:10.1038/s42003-025-07738-0
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
